Profile gets US nod for inhaled therapies technology:
This article was originally published in Clinica
UK firm Profile Therapeutics has received US FDA approval to sell its second-generation adaptive aerosol delivery (AAD) system, Prodose. The product is already available in Europe to deliver Promixin, an inhaled antibiotic for treating patients with cystic fibrosis, and Ventavis, Schering AG's product for pulmonary hypertension. It has also been selected regarding the development of CoTherix' inhaled Iloprost for pulmonary hypertension. A third-generation system, Prodose HandHeld, is in its final stages of development and is expected to be available to patients this year, said Bognor Regis, West Sussex-based Profile Therapeutics. The company is currently in discussions regarding an offer being made for the firm.